Quarterly report pursuant to Section 13 or 15(d)

Organization and Nature of Operations (Details) - Schedule of company's subsidiaries consolidated financial statements

v3.22.2.2
Organization and Nature of Operations (Details) - Schedule of company's subsidiaries consolidated financial statements
 9 Months Ended
Sep. 30, 2022
Avalon Healthcare System, Inc. (“AHS”) [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation Delaware May 18, 2015
Percentage of Ownership 100% held by ALBT
Principal Activities Provides medical related consulting services and developing Avalon Cell and Avalon Rehab in United States of America (“USA”)
Avalon (BVI) Ltd. (“Avalon BVI”) [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation British Virgin Island January 23, 2017
Percentage of Ownership 100% held by ALBT
Principal Activities Dormant, is in process of being dissolved
Avalon RT 9 Properties LLC (“Avalon RT 9”) [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation New Jersey February 7, 2017
Percentage of Ownership 100% held by ALBT
Principal Activities Owns and operates an income-producing real property and holds and manages the corporate headquarters
Avalon (Shanghai) Healthcare Technology Co., Ltd. (“Avalon Shanghai”) [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation PRC April 29, 2016
Percentage of Ownership 100% held by AHS
Principal Activities Ceased operations
Genexosome Technologies Inc. (“Genexosome”) [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation Nevada July 31, 2017
Percentage of Ownership 60% held by ALBT
Principal Activities Dormant
Avactis Biosciences Inc. (''Avactis'') [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation Nevada July 18, 2018
Percentage of Ownership 60% held by ALBT
Principal Activities Integrate and optimize global scientific and clinical resources to further advance cellular therapies, including regenerative medicine with stem/progenitor cells as well as cellular immunotherapy including CAR-T, CAR-NK, TCR-T and others to treat certain cancers
Avactis Nanjing Biosciences Ltd. (“Avactis Nanjing”) [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation PRC May 8, 2020
Percentage of Ownership 100% held by Avactis
Principal Activities Owns a patent
International Exosome Association LLC (''Exosome") [Member]  
Condensed Financial Statements, Captions [Line Items]  
Place and date of Incorporation Delaware June 13, 2019
Percentage of Ownership 100% held by ALBT
Principal Activities Promotes standardization related to exosome industry